Diabetes :: Contributing To The Fight Against Diabetes Is Only A Click Away During American Diabetes Month

More than 20 million Americans suffer from diabetes, a serious, chronic illness. Now, during American Diabetes Month, everyone has an opportunity to make an impact in the fight against the disease, at no cost, with just a click of the mouse. For each visitor who clicks at www.Click4Diabetes.com, a donation will be made to the American Diabetes Association (ADA), the nation’s leading nonprofit health organization providing diabetes research, information and advocacy.

Click4Diabetes is sponsored by King Pharmaceuticals, Inc. and Depomed, Inc. The companies launched Click4Diabetes with a $25,000 donation to the ADA and will contribute an additional $4 for each visitor who clicks at the Web site throughout the month of November, up to a total amount of $100,000.

?With 1 in 14 people living with diabetes in this country and more than twenty percent of Americans at risk of developing the disease, education, awareness and research are more important than ever,? said Brian A. Markison, President and Chief Executive Officer of King Pharmaceuticals. ?We hope through the Click4Diabetes initiative to contribute to the ADA?s efforts to improve the lives of people living with this disease.?

John W. Fara, Ph.D., Chairman, President and Chief Executive Officer of Depomed added, ?Nearly everyone knows someone affected by diabetes, and we?re pleased that we are able to provide an opportunity for people to make a contribution during American Diabetes Month that can help turn the tide against this disease.?

The incidence of diabetes is increasing by approximately 1 million new cases each year in the United States alone. Approximately 90 percent to 95 percent of people with diabetes suffer from type 2 diabetes, the most common metabolic disease in the world and the fifth deadliest disease in the United States. Diabetes is the leading cause of blindness, end-stage renal disease, and nontraumatic loss of limb. It can also lead to heart disease, stroke, high blood pressure, kidney disease, and other serious conditions. In the United States, the public health cost of diabetes is more than $130 billion per year.

King Pharmaceuticals and Depomed market Glumetza? (metformin hydrochloride extended release tablets), a new once-daily extended-release metformin formulation that features AcuForm? drug-delivery technology, for the treatment of adults with type 2 diabetes in the United States.

The Click4Diabetes initiative is sponsored by King Pharmaceuticals, Inc. and Depomed, Inc. The American Diabetes Association is not affiliated with this program and does not endorse any specific diabetes treatment.

To make a donation to the ADA, visit www.click4diabetes.com. For more information about diabetes, visit the ADA?s Web site at www.diabetes.org.

About Glumetza?
Glumetza? (metformin hydrochloride extended-release tablets) is indicated alone or in combination with sulfonylurea or insulin as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes. Glumetza? may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults.

Glumetza? is contraindicated in patients with renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels greater than or equal to 1.5 mg/dL in males and greater than or equal to 1.4 mg/dL in females), known hypersensitivity to metformin HCl, and acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma. As with all metformins, there is a warning regarding lactic acidosis with Glumetza? due to metformin accumulation during treatment. Lactic acidosis is a rare but potentially fatal occurrence. It may also occur in association with a number of pathophysiologic conditions. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient?s age, especially patients ≥80 years of age. In clinical trials of Glumetza combined with a sulfonylurea, the most common side effects included hypoglycemia, diarrhea, and nausea. For additional information on the product, please access the package insert at http://www.depomedinc.com/glumetza_Prescribing_Info.pdf

About King Pharmaceuticals
King (NYSE: KG), headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management. For more information, visit www.kingpharm.com.

About Depomed, Inc.
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm? drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin? XR (ciprofloxacin hydrochloride) extended-release tablets have been approved by the FDA for the once daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once daily Glumetza? (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is currently being marketed in the United States and Canada. The company is conducting a Phase III trial in postherpetic neuralgia and a Phase II trial in diabetic peripheral neuropathy with its product candidate, Gabapentin GR?.